Resources

Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C

Showing 31 to 40 of 266 resources

  • Guidelines on hepatitis B and C testing
    These are the first WHO guidelines on testing for chronic hepatitis B and C infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for hepatitis B and C, and are intended for use across age groups and populations.
    Rest of World Feb 2017 Other, Strategy & Planning PDF
  • Access and Uptake of Direct Acting Antiviral Medicines in the UK and selected European countries
    This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines.
    UK Feb 2017 Reports & Research PDF
  • ChemSex and hepatitis C: a guide for healthcare providers
    A guide for healthcare providers on those at risk of contracting hepatitis C through ChemSex, featuring key facts, transmission risks, suggestions for engaging with those at risk, terms to be familiar with and a case study.
    UK Reports & Research, Tools & Templates PDF
  • National Clinical Guidelines for the treatment of HCV in adults
    These Scottish guidelines, updated in January 2016, provide expert guidance to Health Boards, Area Drug and Therapeutics Committees, and treating clinicians on the efficacy of available treatments for hepatitis C. They also act as a clinical reference source for NHS National Procurement to produce rankings on cost-effectiveness. Development of the guidance was a collaboration between Scotland's viral hepatitis clinical leads and MCN co-ordinators network, National Services Scotland, and Healthcare Improvement Scotland.
    Scotland Jan 2017 Other, Strategy & Planning PDF
  • The 2016 Hep-CORE Report: Monitoring the implementation of hepatitis B and C policy recommendations in Europe
    Published by the European Liver Patients Association, this report provides an overview of the progress made in tackling hepatitis B and C across different European countries, on the basis of surveys undertaken with patient organisations.
    Rest of World Jan 2017 Reports & Research PDF
  • HCV Action and PHE hepatitis C roadshow in Manchester: Presentations
    On 13th December 2016, HCV Action and Public Health England (PHE) staged a hepatitis C good practice roadshow in Manchester. The event was designed to showcase and share best practice in the prevention, diagnosis, testing and treatment of hepatitis C, and identify specific issues and potential solutions for tackling hepatitis C in Manchester and the wider north west region.
    UK, England, North West Other, Strategy & Planning PDF
  • Hepatitis C Commissioning Toolkit
    The Hepatitis C Commissioning Toolkit, an update to the original toolkit published in September 2013, sets out key commissioning responsibilities, with the intention of bringing clarity to an often highly fragmented commissioning landscape. The toolkit is also intended to aide commissioners in commissioning cost-effective services which are tailored to the needs of people with hepatitis C, by setting out how to ensure a clear, connected and properly funded hepatitis C care pathway, as well as providing good practice examples.
    England Case study, Tools & Templates, Strategy & Planning PDF
  • Drug-related infectious diseases in Europe
    This report provides an update on infectious diseases related to drug use in Europe for the period up to June 2016. It covers the most recent data both on infectious diseases among people who inject drugs in Europe, collected with the European Monitoring Centre for Drugs and Drug Addiction Drug-related infectious diseases (DRID) indicator, and on the responses in the area. It includes highlights and new findings discussed during the DRID indicator’s annual expert meeting, held in Lisbon on 6–8 June 2016.
    Rest of World Reports & Research PDF
  • The lived experience of interferon-free treatments for hepatitis C: A thematic analysis
    This research paper, published in the International Journal of Drug Policy, examines how interferon-free treatments for hepatitis C are being understood and experienced by patients.
    UK Reports & Research PDF
  • BBV Bulletin: Quarterly update report of the introduction of opt-out BBV testing in prisons from PHE, NHS England and NOMS
    This bulletin provides an update on the introduction of opt-out BBV testing in prisons across England. It provides an overview of results and findings from the 'phase 2 pathfinder' prisons, as well as a range of recommendations including for prison healthcare teams to work more closely with local ODNs to improve uptake and completion of hepatitis C treatment.
    England Nov 2016 Reports & Research PDF

Pages